Aqualung Therapeutics, Corp

@AqualungCorp

Aqualung Therapeutics Corp. is an early-stage biotech company developing a therapeutic antibody to reduce inflammation in acute and chronic lung diseases.

Tucson, Az
Vrijeme pridruživanja: listopad 2019.

Tweetovi

Blokirali ste korisnika/cu @AqualungCorp

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @AqualungCorp

  1. Prikvačeni tweet

    Aqualung Therapeutics Corporation To Present New Data At Biotech Showcase Investor Conference

    Poništi
  2. Aqualung - Developing Solutions to Unchecked Inflammatory Diseases

    Poništi
  3. Fluid intake-related association between urine output and mortality in acute respiratory distress syndrome

    Poništi
  4. Risk modifiers of acute respiratory distress syndrome in patients with non-pulmonary sepsis: a retrospective analysis of the FORECAST study

    Poništi
  5. Aqualung awarded a $1.7M NIH Fast Track STTR Phase I/II grant

    Poništi
  6. Chorioamnionitis infection is a common complication of pregnancy

    Poništi
  7. Prognostic factors for ARDS: clinical, physiological and atypical immunodeficiency

    Poništi
  8. VpALI—Vaping-related Acute Lung Injury: A New Killer Around the Block

    Poništi
  9. Advances in Pulmonary Hypertension: Exploring Atrial Septal Defect-Associated Pulmonary Hypertension

    Poništi
  10. Aqualung - Developing Solutions to Unchecked Inflammatory Diseases

    Poništi
  11. Flow-Controlled Ventilation Attenuates Lung Injury

    Poništi
  12. Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries

    Poništi
  13. Acute Respiratory Distress Syndrome (ARDS)/Lung Failure

    Poništi
  14. proslijedio/la je Tweet
    16. sij
    Poništi
  15. eNamptor™ is designed to limit activation of evolutionary inflammatory networks and to reduce mortality in serious inflammatory disorders.

    Poništi
  16. Poništi
  17. Aqualung CEO Skip Garcia sharing clinical and under the radar injury through .

    Poništi
  18. Science-driven approach identifies nicotinamide phosphoribosyltransferase (NAMPT) and other key proteins expressed in both acute and chronic inflammatory diseases

    Poništi
  19. Poništi
  20. Aqualung seeking $15M in Series A funding to manufacture its drug to treat inflammatory diseases

    Poništi
  21. Presenting Today 9AM BTS Franciscan B. Aqualung will discuss eNamptor™designed to limit activation of evolutionary inflammatory networks and to reduce mortality in serious inflammatory disorders.

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·